Compare Adaptive Biotechnologies Corp (ADPT) vs Intuit Inc. (INTU) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Intuit (INTU) trades at $272.14, down 1.17% on the day, amid a bearish technical signal and ongoing securities fraud investigations. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust profitability with a net income margin of 21.91%. Revenue growth is steady, climbing from $12.7B in 2022 to $18.8B in 2025, supported by a high gross profit margin of 79.96%.

Despite solid fundamentals, INTU faces significant headwinds from legal scrutiny and negative sentiment, with a 20% stock drop triggering multiple fraud probes. Analyst consensus remains bullish with a $433.69 price target, but near-term risks from litigation and competitive pressures in tax software could limit upside. The stock's current valuation at a P/E of 16.6 offers a margin of safety if growth persists.